Clinical Trials Logo

CD30-Positive Gray Zone Lymphoma clinical trials

View clinical trials related to CD30-Positive Gray Zone Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01994850 Completed - Clinical trials for CD30-Positive Diffuse Large B-Cell Lymphoma

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II multicenter single arm non-randomized open label study of the investigational drug, brentuximab vedotin, given in combination with routine chemotherapy (rituximab, cyclophosphamide, doxorubicin and prednisone) every 3 weeks for a total of 6 cycles.